# Developing preclinical human iPSC-based HTS assays to identify therapeutic agents for biliary atresia

> **NIH NIH R01** · JOHNS HOPKINS UNIVERSITY · 2022 · $368,438

## Abstract

Project Summary
The objective of the research is to develop patient iPSC-based HTS assays that can facilitate
therapeutic discovery for treating biliary atresia (BA) fibrosis. BA is the most common cause of pediatric
end-stage liver disease in the U.S. and is inevitably fatal within the first two years of life if untreated.
Notably, BA is the most rapidly fibrosing liver disease in humans and is associated with significant
morbidity and mortality in children. Compared to other liver diseases that gradually progress into
cirrhosis over decades, BA infants characteristically develop fibrosis/cirrhosis within weeks to months
after birth. Although there is a palliative surgical procedure, there is no known treatment to halt the
progressive fibrosis; most infants born with the disease will need liver transplantation in order to
survive. A main challenge in developing effective anti-fibrotic drugs has been the lack of a model of the
human disease.
The human induced pluripotent stem cell (iPSC) technology provides an alternative for generating
functional, renewable and relevant cell sources for disease modeling using patient tissues. Based on
our expertise on in vitro disease modeling, we have recently succeeded in developing BA patient-
specific iPSCs and have demonstrated that these cells produce significantly more collagen and other
fibrosis markers along with deficiency in biliary differentiation (key disease features of BA), compared to
the iPSCs of healthy children. This new line of research on BA patient iPSCs makes it feasible to
evaluate both efficacy and safety of potential drugs in a more human-relevant setting. Thus we believe
this human cellular model of BA can serve as an ideal system to identify effective anti-fibrotic
compounds in treating liver fibrosis in BA.
In the current study, we propose to: 1) Develop a novel high throughput assay to assess anti-fibrotic
effects of compounds on BA fibrosis using COL1A1 reporter BA-iPSC lines. We will determine the
conditions for miniaturizing the assay and for robust assay automation. 2) Perform pilot screens to
validate and optimize the assay using a clinical drug library in order to ensure automation reliability and
assay reproducibility. 3) Develop independent secondary assays to prioritize hit selection by further
verifying the anti-fibrotic effects of the hits and evaluating their protective/adverse effects on
hepatobiliary tissues derived from patient iPSCs. At the conclusion of this study, we will have
developed a robust, patient cell-based HTS assay capable of identifying new disease targets and leads
for developing novel therapies for BA patients. Moreover, success of this project will be a step forward
in translating basic iPSC discoveries to therapeutic applications, helping to fulfill their promise in
developing regenerative medicine.

## Key facts

- **NIH application ID:** 10434734
- **Project number:** 5R01DK122982-03
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Yoon Young Jang
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $368,438
- **Award type:** 5
- **Project period:** 2020-07-01 → 2023-02-26

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10434734

## Citation

> US National Institutes of Health, RePORTER application 10434734, Developing preclinical human iPSC-based HTS assays to identify therapeutic agents for biliary atresia (5R01DK122982-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10434734. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*